{"nctId":"NCT00577135","briefTitle":"Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)","startDateStruct":{"date":"2008-02"},"conditions":["Heart Failure"],"count":308,"armGroups":[{"label":"Q12 hour bolus","type":"EXPERIMENTAL","interventionNames":["Drug: Furosemide-Low Intensification","Drug: Furosemide-High Intensification"]},{"label":"Continuous Infusion","type":"EXPERIMENTAL","interventionNames":["Drug: Furosemide-Low Intensification","Drug: Furosemide-High Intensification"]},{"label":"Low Intensification","type":"EXPERIMENTAL","interventionNames":["Drug: Furosemide-Q12 hour bolus","Drug: Furosemide-Continuous Infusion"]},{"label":"High Intensification","type":"EXPERIMENTAL","interventionNames":["Drug: Furosemide-Q12 hour bolus","Drug: Furosemide-Continuous Infusion"]}],"interventions":[{"name":"Furosemide-Q12 hour bolus","otherNames":["Loop diuretics"]},{"name":"Furosemide-Continuous Infusion","otherNames":["Loop diuretic"]},{"name":"Furosemide-Low Intensification","otherNames":["Loop diuretic"]},{"name":"Furosemide-High Intensification","otherNames":["loop diuretic"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Prior clinical diagnosis of heart failure that was treated with daily oral loop diuretics for at least 1 month\n* Current diagnosis of heart failure, as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography)\n* Daily oral dose of furosemide between 80 mg and 240 mg (or equivalent)\n* Identified within 24 hours of hospital admission\n* Current treatment plan includes IV loop diuretics for at least 48 hours\n\nExclusion Criteria:\n\n* Brain natriuretic peptide (BNP) less than 250 mg/mL or N-terminal prohormone brain natriuretic peptide (NT-proBNP) less than 1000 mg/mL\n* Received IV vasoactive treatment or ultra-filtration therapy for heart failure since initial presentation\n* Treatment plan during current hospitalization includes IV vasoactive treatment or ultra-filtration for heart failure\n* Substantial diuretic response to pre-randomization diuretic dosing such that higher doses of diuretics would be medically inadvisable\n* Systolic blood pressure less than 90 mm Hg\n* Serum creatinine level greater than 3.0 mg/dL at baseline or currently undergoing renal replacement therapy\n* Hemodynamically significant arrhythmias\n* Acute coronary syndrome within 4 weeks prior to study entry\n* Active myocarditis\n* Hypertrophic obstructive cardiomyopathy\n* Severe stenotic valvular disease\n* Restrictive or constrictive cardiomyopathy\n* Complex congenital heart disease\n* Constrictive pericarditis\n* Non-cardiac pulmonary edema\n* Clinical evidence of digoxin toxicity\n* Need for mechanical hemodynamic support\n* Sepsis\n* Terminal illness (other than heart failure) with expected survival time of less than 1 year\n* History of adverse reaction to the study drugs\n* Use of IV iodinated radiocontrast material within 72 hours prior to study entry or planned during hospitalization\n* Enrollment or planned enrollment in another randomized clinical trial during this hospitalization\n* Inability to comply with planned study procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Well Being, as Determined by a Visual Analog Scale","description":"Global Visual Analog Scale Scale Range 0-7200; higher score is better","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4236","spread":"1440.4"},{"groupId":"OG001","value":"4372.7","spread":"1404.4"},{"groupId":"OG002","value":"4170.8","spread":"1436.3"},{"groupId":"OG003","value":"4429.6","spread":"1401.4"}]}]}]},{"type":"PRIMARY","title":"Change in Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.30"},{"groupId":"OG001","value":"0.07","spread":"0.30"},{"groupId":"OG002","value":"0.04","spread":"0.29"},{"groupId":"OG003","value":"0.08","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change in Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"7.8"},{"groupId":"OG001","value":"-9.1","spread":"10.2"},{"groupId":"OG002","value":"-7.4","spread":"10.1"},{"groupId":"OG003","value":"-9.6","spread":"7.9"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Free of Congestion","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"15.3","spread":null},{"groupId":"OG002","value":"11.2","spread":null},{"groupId":"OG003","value":"18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Dyspnea, as Determined by Visual Analog Scales","description":"Global Visual Analog Scale Scale Range 0-2400; higher score is better","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1370.8","spread":"486.0"},{"groupId":"OG001","value":"1453.8","spread":"518.0"},{"groupId":"OG002","value":"1426.0","spread":"504.5"},{"groupId":"OG003","value":"1398.2","spread":"502.7"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.18"},{"groupId":"OG001","value":"0.01","spread":"0.17"},{"groupId":"OG002","value":"-0.01","spread":"0.16"},{"groupId":"OG003","value":"0.02","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in Cystatin C","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.30"},{"groupId":"OG001","value":"0.17","spread":"0.35"},{"groupId":"OG002","value":"0.12","spread":"0.35"},{"groupId":"OG003","value":"0.17","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.23"},{"groupId":"OG001","value":"0.05","spread":"0.26"},{"groupId":"OG002","value":"0.01","spread":"0.23"},{"groupId":"OG003","value":"0.06","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.32"},{"groupId":"OG001","value":"0.05","spread":"0.32"},{"groupId":"OG002","value":"0.05","spread":"0.33"},{"groupId":"OG003","value":"0.07","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.40"},{"groupId":"OG001","value":"0.04","spread":"0.32"},{"groupId":"OG002","value":"0.07","spread":"0.33"},{"groupId":"OG003","value":"0.08","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.41"},{"groupId":"OG001","value":"0.07","spread":"0.45"},{"groupId":"OG002","value":"0.09","spread":"0.43"},{"groupId":"OG003","value":"0.07","spread":"0.43"}]}]}]},{"type":"SECONDARY","title":"Patient Well Being, as Determined by a Visual Analog Scale","description":"Global Visual Analog Scale Scale Range 0-2400; higher score is better","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1280.8","spread":"469.7"},{"groupId":"OG001","value":"1303.0","spread":"465.1"},{"groupId":"OG002","value":"1288.6","spread":"455.9"},{"groupId":"OG003","value":"1294.8","spread":"478.4"}]}]}]},{"type":"SECONDARY","title":"Patient Well Being, as Determined by a Visual Analog Scale","description":"Global Visual Analog Scale Scale Range 0-4800; higher score is better","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2722.6","spread":"940.0"},{"groupId":"OG001","value":"2792.6","spread":"932.7"},{"groupId":"OG002","value":"2706.5","spread":"931.5"},{"groupId":"OG003","value":"2805.2","spread":"939.8"}]}]}]},{"type":"SECONDARY","title":"Dyspnea VAS","description":"Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2876.6","spread":"960.1"},{"groupId":"OG001","value":"3033.1","spread":"1039.3"},{"groupId":"OG002","value":"2924.9","spread":"1012.8"},{"groupId":"OG003","value":"2981.3","spread":"992.9"}]}]}]},{"type":"SECONDARY","title":"Dyspnea VAS","description":"Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4455.6","spread":"1468.4"},{"groupId":"OG001","value":"4699.1","spread":"1572.7"},{"groupId":"OG002","value":"4477.9","spread":"1549.7"},{"groupId":"OG003","value":"4668.3","spread":"1496.0"}]}]}]},{"type":"SECONDARY","title":"Change in Cystatin C","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.43"},{"groupId":"OG001","value":"0.16","spread":"0.48"},{"groupId":"OG002","value":"0.16","spread":"0.48"},{"groupId":"OG003","value":"0.21","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Change in Cystatin C","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.51"},{"groupId":"OG001","value":"0.16","spread":"0.43"},{"groupId":"OG002","value":"0.18","spread":"0.47"},{"groupId":"OG003","value":"0.18","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Change in Uric Acid","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.02"},{"groupId":"OG001","value":"0.44","spread":"1.20"},{"groupId":"OG002","value":"0.11","spread":"1.01"},{"groupId":"OG003","value":"0.61","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Change in Uric Acid","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"1.47"},{"groupId":"OG001","value":"0.09","spread":"1.96"},{"groupId":"OG002","value":"0.07","spread":"1.69"},{"groupId":"OG003","value":"0.42","spread":"1.75"}]}]}]},{"type":"SECONDARY","title":"Change in Uric Acid","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"2.28"},{"groupId":"OG001","value":"-0.71","spread":"2.27"},{"groupId":"OG002","value":"-0.13","spread":"2.33"},{"groupId":"OG003","value":"-0.67","spread":"2.24"}]}]}]},{"type":"SECONDARY","title":"Change in B-type Natriuretic Peptide","description":"Change in NTproBNP","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1316.2","spread":"4364.3"},{"groupId":"OG001","value":"-1773.2","spread":"3827.5"},{"groupId":"OG002","value":"-1193.8","spread":"4094.1"},{"groupId":"OG003","value":"-1881.6","spread":"4105.4"}]}]}]},{"type":"SECONDARY","title":"Change in NTproBNP","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1133.3","spread":"4883.4"},{"groupId":"OG001","value":"-1552.0","spread":"4875.8"},{"groupId":"OG002","value":"-1037.2","spread":"5211.8"},{"groupId":"OG003","value":"-1629.7","spread":"4524.6"}]}]}]},{"type":"SECONDARY","title":"Change in NTproBNP","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1449.3","spread":"5010.1"},{"groupId":"OG001","value":"-1035.1","spread":"6962.9"},{"groupId":"OG002","value":"-1445.6","spread":"5805.3"},{"groupId":"OG003","value":"-1038.5","spread":"6364.3"}]}]}]},{"type":"SECONDARY","title":"Presence of Cardiorenal Syndrome","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"19.2","spread":null},{"groupId":"OG002","value":"13.6","spread":null},{"groupId":"OG003","value":"22.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Failure","description":"Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null},{"groupId":"OG001","value":"38.8","spread":null},{"groupId":"OG002","value":"36.7","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Net Fluid Loss","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1595.7","spread":"1476.7"},{"groupId":"OG001","value":"1796.4","spread":"1685.1"},{"groupId":"OG002","value":"1209.7","spread":"1309.3"},{"groupId":"OG003","value":"2149.6","spread":"1681.7"}]}]}]},{"type":"SECONDARY","title":"Net Fluid Loss","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2996.7","spread":"2490.5"},{"groupId":"OG001","value":"3120.6","spread":"2504.2"},{"groupId":"OG002","value":"2334.8","spread":"2006.4"},{"groupId":"OG003","value":"3747.4","spread":"2716.1"}]}]}]},{"type":"SECONDARY","title":"Net Fluid Loss","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4236.7","spread":"3207.6"},{"groupId":"OG001","value":"4249.2","spread":"3104.3"},{"groupId":"OG002","value":"3575.2","spread":"2634.8"},{"groupId":"OG003","value":"4898.9","spread":"3478.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":69,"n":156},"commonTop":[]}}}